FDA advisory committee vote in favor of Lundbeck and Otsuka's Alzheimer's agitation drug Rexulti
Advisory committee at the FDA have voted in favor of Lundbeck and Otsuka Pharmaceuticals’ Brexpiprazole for the treatment of Alzheimer’s agitation.
by marketwire & medwatch
An advisory committee at the Food and Drug Administration (FDA), on Friday voted in favor of approving Lundbeck and Otsuka Pharmaceuticals’ Brexpiprazole for the treatment of agitation in Alzheimer’s patients.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
